Larimar Therapeutics Reports Positive Data From Phase 1 Trial of Friedreich's Ataxia Treatment; Shares Up Pre-Bell
08:40 AM EDT, 05/11/2021 (MT Newswires) -- Larimar Therapeutics (LRMR) on Tuesday reported positive topline data from a phase 1 trial evaluating CTI-1601 to treat Friedreich's ataxia disease.
The biotech company said trial data show that repeated subcutaneous administration of CTI-1601 resulted in dose-dependent increases in frataxin levels from baseline compared to placebo controls.
"The ability of CTI-1601 to elevate frataxin in the evaluated tissues strongly supports its continued clinical evaluation, as frataxin levels in buccal cells and blood have been shown to be associated with disease severity in FA patients," said Chief Medical Officer Nancy Ruiz.
Shares of Larimar Therapeutics were up nearly 7% in premarket trading.
Price: 13.74, Change: +0.62, Percent Change: +4.73